Accreditation

How to Claim CME, MOC, or Receive Certificate of Participation 

EBR 2024 Virtual Meeting is eligible for 55 AMA PRA Category 1 Credits™ and ABIM MOC points. Learners may claim CME credits and MOC points upon completion of the activity by following the steps below. CME credits and/or MOC points for this activity must be claimed by December 31, 2024. 

Follow the steps below to claim credits: 

• STEP 1: Visit education.endocrine.org. 
• STEP 2: Log in (upper right corner of page). 
• STEP 3: Click My Courses and select the corresponding evaluation. 

**Note: while the virtual meeting includes the exam book, registrants of the virtual meeting will only be eligible to claim credit for the virtual meeting. 
 

Accreditation 

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation. 
 

AMA PRA CATEGORY 1 CREDITS™ 

The Endocrine Society designates this enduring activity for a maximum of 55 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field. 

Please note that while other accrediting bodies accept  AMA PRA Category 1 Credit™, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body. 
 

 

Maintenance of Certification (MOC) 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 55 points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits. 

Target Audience 
This activity is intended for endocrine fellows planning for initial certification, practicing endocrinologists preparing for an MOC assessment, or physicians seeking an in-depth review of endocrinology. The secondary target audience includes advanced practice nurses and physician assistants. 
 

Learning Objectives 
Upon completion of this educational activity, learners will be able to: 

• Demonstrate enhanced medical knowledge and clinical skills across all major areas of endocrinology. 
• Apply knowledge and skills in diagnosing, managing, and treating a wide spectrum of endocrine disorders. 
• Successfully completed the board examination for certification or recertification in the subspecialty of endocrinology, diabetes, and metabolism. 
   

Statement of Independence 
As a provider of CME accredited by the ACCME, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's EBR faculty. There are no commercial supporters of this activity, and no commercial entities have had influence over the planning of this CME activity. 

Disclosure Policy 
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. 

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable. 
 

The following faculty reported relevant financial relationships: 

John D. Carmichael, MD, Novo Nordisk: Advisory Board Member; Recordati: Advisory Board Member; Camurus: Advisory Board Member  

Natalie Cusano, MD, MS, Takeda/Shire: Research Funds; Ascendis Pharma: Consultant; Alexion: Speaker  

Tobias Else, MD, Corcept Pharmaceuticals: Co-Investigator; Merck: Advisor Board Member, Co-Investigator; Lantheus: Advisory Board Member; VHL Alliance: Committee Member  

Sangeeta Kashyap, MD, GI Dynamics: Investigator, Consultant; Fractyl: Research Support; Gila Therapeutics: Chief Medical Officer  

Eisai: Trial Event Adjudicator; Dexcom: Research Grant  

Stephanie Page, MD, PhD: Pharmajor International: Consultant

Anne Peters, MD, Lilly: Advisory Board; Medscape: Advisory Board; Vertex: Advisory Board; Insulet: Research Support; Abbott Diabetes Care: Research Support; Omada Health: Stock Options  

The following faculty reported no relevant financial relationships:  Frances J. Hayes, MB BCh BAO; Jacqueline Jonklaas, MD, PhD, MPH; Kaniksha Desai, MD, Margaret Flynn Lippincott, MD; and Marie E. McDonnell, MD  

The medical editor for this activity reported no relevant financial relationships:  Abbie L. Young, MS, CGC, ELS(D) 
 

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships. 
 

Acknowledgement of Commercial Support 
The activity is not supported by educational grant(s) or other funds from any commercial supporters.